FDA Risk Communication Research May Follow Critical Path To Avoid OMB
FDA may need to undertake an approach similar to the agency's Critical Path initiative in order to facilitate research evaluating its communication efforts
You may also be interested in...
After GAO finds FDA one of the slower agencies in rulemaking, Rep. Towns asks for timeliness and transparency in White House input on federal regulations.
Senate confirmation hearing focuses on access issues as much as it addresses regulation of medical products.
FDA's ongoing challenges with effectively communicating the risks indicated by postmarket safety signals need to be resolved before the agency activates its Sentinel surveillance program, a number of participants said during a Dec. 16 FDA workshop